My Treatment Approach: Targeting HER2 in Metastatic Colorectal Cancer

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

A pathologist explains how she chooses between a variety of molecular testing technology options in colorectal cancer.

Experts describe which patients should be screened for HER2 amplification in colorectal cancer and how best to detect it.

Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.

A look at how the molecular testing landscape in colorectal cancer is evolving.

Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.

Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

Experts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.